Allarity keeps streamlining pipeline – sells cancer drug for USD 18m

Biotech company Allarity Therapeutics has divested a drug candidate to US Lantern Pharma, from which the Danish company in-licensed the drug in 2015. The deal may amount to USD 18m.
Photo: Allarity Therapeutics / PR
Photo: Allarity Therapeutics / PR

Danish medical company Allarity Therapeutics has divested the drug Irufulven to US-stocklisted company Lantern Pharma. The total price including an upfront payment and development and regulatory milestone fees may amount to around USD 18m, not including the royalties the company can earn from the sales, according to a Monday press release from the Danish company, which is listed in Sweden.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading